Tim F. Greten, M.D.
Dr. Greten is an expert in gastrointestinal (GI) oncology and tumor immunology. His specific research focus is hepatocellular carcinoma and tumor immunology. He is trying to better understand how tumors in the liver interact with the immune system. Dr. Greten received his training in medical oncology, gastroenterology and hepatology in Germany and he has been performing basic and translational research studies in tumor immunology for more than 20 years. He is currently studying novel immune-based approaches to treat patients with hepatocellular carcinoma, cholangiocarcinoma and tumors of the GI tract metastasizing into the liver. Dr. Greten is cochair of the Center of Excellence in Immunology and co-director of the NCI CCR Liver Cancer Program.
1) gastrointestinal cancer, 2) tumor immunology and immunotherapy, 3) hepatocellular carcinoma, 4) liver immunology and cancer, 5) preclinical and translational studies
Dr. Greten combines his medical expertise in gastroenterology, hepatology and medical oncology with his research expertise in tumor immunology. His research can be best described by the three terms “liver”, “cancer “ and “immunology”. Dr. Greten and his team try to better understand how tumors in the liver interact with the immune system and he utilized this knowledge to develop better treatment options for patients with tumors of the GI tract. Dr. Greten is an expert on immune suppressor mechanisms occurring in patients with liver cancer (and murine models of liver cancer). In his recent work published in Nature in Science he studied how liver disease and the gut microbiome control anti-tumor immunity in the liver. Dr. Greten is also principle investigator of a number of immunotherapy trials in patients with GI cancer and pioneered the combination of locoregional and immune checkpoint blockade in HCC.
What's Next in Liver Cancer Research - Twitter Live
Selected Key Publications
- Science. 360(6391): 2018. [ Journal Article ]
Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression..Cancer Cell. 30(4): 533-47, 2016. [ Journal Article ]
- Nature. 531(7593): 253-7, 2016. [ Journal Article ]
- Journal of Hepatology. 66(3): 545-551, 2017. [ Journal Article ]
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.Gastroenterology. 135(1): 234-43, 2008. [ Journal Article ]
Tim F. Greten, M.D., received his medical training at Christian Albrechts University in Kiel, Germany in 1993. He did his internship in Munich followed by a 3-year postdoctoral fellowship at the Johns Hopkins University (Baltimore, Maryland), where he initiated his work in the field of tumor immunology. In 1999 Dr. Greten returned to Hannover Medical School, where he finished his training in Internal Medicine (2003), Medical Oncology (2004) and Gastroenterology (2007). He held an Associate Professor position in the Department of Gastroenterology, Hepatology and Endocrinology. In February 2010 Dr. Greten joined CCR's Medical Oncology Branch as head of the Gastrointestinal Malignancy Section and was promoted as a tenured Senior Investigator in 2015 and Deputy Branch Chief in 2018.
Dr. Greten has published more than 150 peer-reviewed papers on basic tumor immunology, translational research studies in hepatocellular carcinoma (HCC) as well as on clinical trials in different gastrointestinal malignancies, including HCC. Dr. Greten is co-chair of the Center of Excellence in Immunology, member of the Center for Advanced Preclinical Research oversight committee and the NCI Drug Development Collaborative, Co-Director of the NCI-CCR-Liver Cancer Program. and chairs the steering committee of the CCR Center for Cell-based Therapy.
|Position||Degree Required||Contact Name||E-mail Address|
|Post-doctoral Fellow - Tumor immunology, liver cancer||Ph.D. or equivalent, M.D. or equivalent||Tim Greten||Tim.email@example.com|
|Elizabeth Akoth R.N.||Research Nurse|
|Vanessa Catania||Postbaccalaureate Fellow (CRTA)|
|Angelicia Garrison||Patient Care Coordinator (Contr.)|
|Bernd Heinrich Ph.D.||Postdoctoral Fellow (Visiting)|
|Chi Ma Ph.D.||Staff Scientist|
|Donna Mabry Hrones C.R.N.P.||Nurse Practitioner|
|Dariele Marshall||Administrative Assistant (Contr.)|
|Jack McVey||MRSP Fellow|
|Cecilia Monge, M.D., M.P.H., FACP||Staff Clinician|
|Kamil Rechache M.D.||Medical Oncology Fellow|
|Benjamin Ruf M.D.||Postdoctoral Fellow (Visiting)|
|Simon Wabitsch||Special Volunteer|
|Sophie (Chunhui) Wang||Biologist|
|Santhana Webb R.N.||Research Nurse|
|Qianfei Zhang Ph.D.||Postdoctoral Fellow (Visiting)|
Associate Professor, University College Dublin, Ireland
Assistant Research Physician, Genitourinary Malignancies Branch, NCI
Dana-Farber Cancer Institute
University of Michigan
Stephenson Cancer Center
Physician-Scientist Early Invesitgator, Thoracic and GI Malignancies Branch, NCI
University of Frankfurt, Germany
Medizinische Hochschule Hanover, Germany
Medizinische Hochschule Hannover, Germany
Medizinische Hochschule Hannover, Germany
May 14, 2019
Dr. Greten's new study on whether antibodies can boost immune response in treating liver cancer. Learn more...
CCR Milestones 2019
A discovery in Dr. Greten's laboratory offers a clear example of how bacteria that live in the gut can hinder the immune system's ability to control tumors in the liver. Learn more...
January 28, 2019
A new, early-phase clinical trial marks and important stepping stone toward pinpointing which patients may benefit most from a combination of a new class of immunotherapy drugs called immune checkpoint inhibitors with radiation therapy. Learn more...
CCR Milestones 2017
Dr. Greten's study on non-alcohlic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC) was recognized as one of CCR's top cancer research milestones in 2017. Learn more...
Clinical trial shows safety and effectiveness of new combination immunotherapy for advanced liver cancer
May 1, 2017
This recently completed phase I clinical trial at the NIH Clinical Center in Bethesda, Maryland, demonstrates that a combination of two immunotherapy drugs to target HCC was well-tolerated and shrunk tumors in a larger percentage of patients than the standard chemotherapy. Learn more...